$1.76 Billion is the total value of Perceptive Advisors's 173 reported holdings in Q1 2017. The portfolio turnover from Q4 2016 to Q1 2017 was 114.1% .
| Value | Shares | ↓ Weighting | ||||||
|---|---|---|---|---|---|---|---|---|
| LLY | Exit | ELI LILLY & CO CALL 90 01/20/2017call | $0 | – | -100,000 | -100.0% | 0.00% | – |
| NEOS | Exit | NEOS THERAPEUTICS | $0 | – | -1,056 | -100.0% | 0.00% | – |
| TMO | Exit | THERMO FISHER SCIENTIFIC | $0 | – | -2 | -100.0% | 0.00% | – |
| OPHT | Exit | OPHTHOTECH CORP CALL 75 01/20/2017call | $0 | – | -220,400 | -100.0% | 0.00% | – |
| IPXL | Exit | IMPAX LABORATORIES | $0 | – | -1 | -100.0% | 0.00% | – |
| GLD | Exit | SPDR GOLD SHARES ETF | $0 | – | -1 | -100.0% | 0.00% | – |
| MRTX | Exit | MIRATI THERAPEUTICS | $0 | – | -521 | -100.0% | 0.00% | – |
| ZTS | Exit | ZOETIS CLASS A | $0 | – | -3 | -100.0% | 0.00% | – |
| SGMO | Exit | SANGAMO BIOSCIENCES | $0 | – | -272 | -100.0% | 0.00% | – |
| AVGR | Exit | AVINGER | $0 | – | -1,062 | -100.0% | 0.00% | – |
| CTLT | Exit | CATALENT | $0 | – | -3 | -100.0% | 0.00% | – |
| ACAD | Exit | ACADIA PHARMACEUTICALS INC CALL 40 01/20/2017call | $0 | – | -100,000 | -100.0% | 0.00% | – |
| DVA | Exit | DAVITA | $0 | – | -3 | -100.0% | 0.00% | – |
| JNJ | Exit | JOHNSON and JOHNSON | $0 | – | -2 | -100.0% | 0.00% | – |
| INNL | Exit | INNOCOLL | $0 | – | -9,433 | -100.0% | 0.00% | – |
| FLKS | Exit | FLEX PHARMA | $0 | – | -237 | -100.0% | 0.00% | – |
| CRBP | Exit | CORBUS PHARMACEUTICALS HOLDINGS INC CALL 15 01/20/2017call | $0 | – | -1,600 | -100.0% | 0.00% | – |
| BRKR | Exit | BRUKER | $0 | – | -3 | -100.0% | 0.00% | – |
| DIA | Exit | SPDR DOW JONES INDUSTRIAL AVERAGE ETF | $0 | – | -3 | -100.0% | 0.00% | – |
| DVAX | Exit | DYNAVAX TECHNOLOGIES CALL 4 01/2017call | $0 | – | -15,600 | -100.0% | 0.00% | – |
| XBI | Exit | SPDR SandP BIOTECH ETF | $0 | – | -50 | -100.0% | 0.00% | – |
| GKOS | Exit | GLAUKOS | $0 | – | -300 | -100.0% | -0.00% | – |
| SUPN | Exit | SUPERNUS PHARMACEUTICALS | $0 | – | -421 | -100.0% | -0.00% | – |
| INGN | Exit | INOGEN | $0 | – | -125 | -100.0% | -0.00% | – |
| ARIA | Exit | ARIAD PHARMACEUTICALS | $0 | – | -1,551 | -100.0% | -0.00% | – |
| VCEL | Exit | VERICEL | $0 | – | -9,385 | -100.0% | -0.00% | – |
| OPHT | Exit | OPHTHOTECH CORP PUT 20 01/20/2017put | $0 | – | -1,600 | -100.0% | -0.00% | – |
| CEMP | Exit | CEMPRA | $0 | – | -22,321 | -100.0% | -0.00% | – |
| CYNO | Exit | CYNOSURE CLASS A | $0 | – | -1,800 | -100.0% | -0.01% | – |
| STML | Exit | STEMLINE THERAPEUTICS | $0 | – | -10,702 | -100.0% | -0.01% | – |
| MDGWW | Exit | AEVI GENOMIC MEDICINE WARRANTwarrants | $0 | – | -150,000 | -100.0% | -0.01% | – |
| PMD | Exit | PSYCHEMEDICS | $0 | – | -6,626 | -100.0% | -0.01% | – |
| FVE | Exit | FIVE STAR QUALITY CARE | $0 | – | -67,797 | -100.0% | -0.01% | – |
| GNVC | Exit | GENVEC | $0 | – | -56,131 | -100.0% | -0.01% | – |
| MACK | Exit | MERRIMACK PHARMACEUTICALS | $0 | – | -48,910 | -100.0% | -0.01% | – |
| NTLA | Exit | INTELLIA THERAPEUTICS | $0 | – | -14,673 | -100.0% | -0.01% | – |
| ENDP | Exit | ENDO INTERNATIONAL | $0 | – | -12,920 | -100.0% | -0.02% | – |
| PBYI | Exit | PUMA BIOTECHNOLOGY | $0 | – | -7,344 | -100.0% | -0.02% | – |
| Exit | PERNIX THERAPEUTICS HOLD 01APR21 4.25PCTnote | $0 | – | -1,000,000 | -100.0% | -0.02% | – | |
| SRPT | Exit | SAREPTA THERAPEUTICS INC PUT 50 01/20/2017put | $0 | – | -10,900 | -100.0% | -0.02% | – |
| NVLS | Exit | NIVALIS THERAPEUTICS | $0 | – | -122,275 | -100.0% | -0.02% | – |
| IRIX | Exit | IRIDEX | $0 | – | -21,885 | -100.0% | -0.02% | – |
| PZRXQ | Exit | PHASERX | $0 | – | -200,000 | -100.0% | -0.02% | – |
| MOH | Exit | MOLINA HEALTHCARE | $0 | – | -6,981 | -100.0% | -0.03% | – |
| SCMP | Exit | SUCAMPO PHARMACEUTICALS CLASS A | $0 | – | -30,694 | -100.0% | -0.03% | – |
| NVAX | Exit | NOVAVAX | $0 | – | -335,413 | -100.0% | -0.03% | – |
| IMDZ | Exit | IMMUNE DESIGN | $0 | – | -77,725 | -100.0% | -0.03% | – |
| ESRX | Exit | EXPRESS SCRIPTS HOLDING | $0 | – | -6,639 | -100.0% | -0.03% | – |
| AGTC | Exit | APPLIED GENETIC TECHNOLOGIES | $0 | – | -50,251 | -100.0% | -0.03% | – |
| AMN | Exit | AMN HEALTHCARE | $0 | – | -12,585 | -100.0% | -0.03% | – |
| ICLR | Exit | ICON | $0 | – | -6,873 | -100.0% | -0.04% | – |
| HUM | Exit | HUMANA INC CALL 210 04/21/2017call | $0 | – | -40,000 | -100.0% | -0.04% | – |
| CCRN | Exit | CROSS COUNTRY HEALTHCARE | $0 | – | -34,819 | -100.0% | -0.04% | – |
| SCYX | Exit | SCYNEXIS | $0 | – | -171,185 | -100.0% | -0.04% | – |
| BIIB | Exit | BIOGEN INC | $0 | – | -1,922 | -100.0% | -0.04% | – |
| MGLN | Exit | MAGELLAN HEALTH | $0 | – | -7,508 | -100.0% | -0.04% | – |
| ENZ | Exit | ENZO BIOCHEM | $0 | – | -83,893 | -100.0% | -0.04% | – |
| INCR | Exit | INC RESEARCH HOLDINGS CLASS A | $0 | – | -12,636 | -100.0% | -0.05% | – |
| EXAS | Exit | EXACT SCIENCES CORP PUT 17 01/20/2017put | $0 | – | -200,000 | -100.0% | -0.05% | – |
| UTHR | Exit | UNITED THERAPEUTICS | $0 | – | -4,753 | -100.0% | -0.05% | – |
| ACHI | Exit | ACCRETIVE HEALTH | $0 | – | -315,000 | -100.0% | -0.05% | – |
| BCLI | Exit | BRAINSTORM CELL THERAPEUTICS | $0 | – | -400,000 | -100.0% | -0.07% | – |
| VXX | Exit | BARCLAYS BANK IPATH SandP 500 VIX SHORT TERM FUTURES ETN EXP | $0 | – | -41,000 | -100.0% | -0.07% | – |
| MDCO | Exit | MEDICINES CO PUT 32 04/21/2017put | $0 | – | -200,000 | -100.0% | -0.08% | – |
| Exit | NEURODERM | $0 | – | -57,825 | -100.0% | -0.09% | – | |
| PFE | Exit | PFIZER | $0 | – | -55,000 | -100.0% | -0.13% | – |
| MYOV | Exit | MYOVANT SCIENCES | $0 | – | -226,322 | -100.0% | -0.20% | – |
| CELG | Exit | CELGENE | $0 | – | -26,000 | -100.0% | -0.21% | – |
| COLL | Exit | COLLEGIUM PHARMACEUTICAL | $0 | – | -196,728 | -100.0% | -0.22% | – |
| BCRX | Exit | BIOCRYST PHARMACEUTICALS | $0 | – | -1,330,240 | -100.0% | -0.60% | – |
| ACOR | Exit | ACORDA THERAPEUTICS | $0 | – | -720,000 | -100.0% | -0.96% | – |
| CLCD | Exit | COLUCID PHARMACEUTICALS | $0 | – | -641,364 | -100.0% | -1.66% | – |
| EGRX | Exit | EAGLE PHARMACEUTICALS | $0 | – | -498,198 | -100.0% | -2.81% | – |
Original filings
The following EDGAR filing(s) were analyzed to create this report:
- View 13F-HR filed 2017-05-15
About Perceptive Advisors
Perceptive Advisors is a New York-based hedge fund that specializes in healthcare investments. The company was founded in 1999 by Joseph Edelman, who serves as the CEO and Chief Investment Officer. Since its inception, Perceptive Advisors has become one of the most successful healthcare-focused hedge funds in the world, with over $5 billion in assets under management.
The company's investment strategy is based on a deep understanding of the healthcare industry and a focus on identifying promising companies with innovative products and technologies. Perceptive Advisors invests in a wide range of healthcare sectors, including biotechnology, pharmaceuticals, medical devices, and healthcare services.
One of the key factors behind Perceptive Advisors' success is its team of experienced professionals. In addition to Joseph Edelman, the company's leadership team includes Adam Stone, the COO, and Jeremy Goldberg, the Chief Scientific Officer. The team also includes a group of highly skilled analysts and researchers who are experts in their respective fields.
Perceptive Advisors has a strong track record of generating high returns for its investors. However, it is important to note that investing in hedge funds carries significant risks, and investors should carefully consider their investment objectives and risk tolerance before investing. As with any investment, it is important to conduct thorough research and seek the advice of a qualified financial advisor before making any investment decisions.
It's important to note that this information is for educational purposes only and has not been fact-checked. As with any investment, it's important to do your own research and consult with a financial advisor before making any investment decisions.
Top long-term holdings
| Name | Quarters owned | Latest quarter owned | Max weighting |
|---|---|---|---|
| NEUROCRINE BIOSCIENCES SHARES | 42 | Q3 2023 | 15.7% |
| AMICUS THERAPEUTICS SHARES | 39 | Q3 2023 | 14.0% |
| ALDEYRA THERAPEUTICS SHARES | 35 | Q3 2023 | 3.3% |
| QUOTIENT TECHNOLOGY INC | 34 | Q3 2022 | 2.7% |
| GLOBAL BLOOD THERAPEUTICS SHARES | 29 | Q3 2022 | 9.3% |
| ADMA BIOLOGICS SHARES | 29 | Q3 2023 | 1.4% |
| RETROPHIN SHARES | 28 | Q3 2020 | 5.5% |
| DBV TECHNOLOGIES SA-SPON ADR | 28 | Q3 2021 | 1.8% |
| VBI VACCINES SHARES | 27 | Q1 2023 | 2.8% |
| IOVANCE BIOTHERAPEUTICS INC | 26 | Q3 2023 | 9.1% |
View Perceptive Advisors's complete holdings history.
Latest significant ownerships (13-D/G)
| Filed | Shares | Percentage | |
|---|---|---|---|
| CHEMBIO DIAGNOSTICS, INC.Sold out | May 04, 2023 | 0 | 0.0% |
| VBI Vaccines Inc/BC | April 07, 2023 | 43,509,553 | 16.7% |
| Landos Biopharma, Inc. | March 30, 2023 | 14,869,915 | 47.7% |
| REATA PHARMACEUTICALS INC | March 07, 2023 | 2,083,799 | 6.5% |
| AGILE THERAPEUTICS INCSold out | February 14, 2023 | 0 | 0.0% |
| ALBIREO PHARMA, INC. | February 14, 2023 | 1,757,160 | 8.5% |
| BELLUS Health Inc. | February 14, 2023 | 8,891,027 | 7.1% |
| CinCor Pharma, Inc. | February 14, 2023 | 2,576,325 | 5.9% |
| Coherus BioSciences, Inc.Sold out | February 14, 2023 | 0 | 0.0% |
| CONCERT PHARMACEUTICALS, INC. | February 14, 2023 | 1,800,000 | 3.6% |
View Perceptive Advisors's complete significant-ownership history.
Latest filings
| Type | Filed |
|---|---|
| SC 13D/A | 2024-05-01 |
| SC 13D/A | 2024-04-17 |
| SC 13D/A | 2024-04-17 |
| 4 | 2024-04-15 |
| SC 13G/A | 2024-04-15 |
| SC 13G | 2024-04-15 |
| SC 13D/A | 2024-04-10 |
| 4 | 2024-04-08 |
| 4 | 2024-04-03 |
| SC 13D/A | 2024-04-03 |
View Perceptive Advisors's complete filings history.
All filings
- Holdings (13F-HR)
- Significant ownership (13-D/G)
- Insider transactions (4, 5, 6)
- Events (8-K)
- Shareholder votes (proxy)
View complete filings history.